Ironwood Pharmaceuticals (IRWD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.36
- Estimate
- $0.31
- Surprise
- +16.1%
- Revenue (period 2026-09-30)
- $133.0M
- Score at report (before → after)
- 7.6 → 7.5/10
Revenue source: xbrl.
How the report landed
Ironwood Pharmaceuticals (IRWD) beat the $0.31 estimate with adjusted EPS of $0.36 — a large 16.1% upside surprise. TrendMatrix's engine moved from Strong Buy (7.6/10) to Buy (Wait) at 7.5/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IRWD Buy (Wait) at 7.6/10.
2 of the last 4 quarters beat the estimate; this quarter's +16.1% surprise compares with a -57.0% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.9 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Overbought (RSI 77)
- R/R 1.2x at spot < 1.5 minimum
- Reward/Risk 1.2:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.41
- Entry target
- $4.27
- Price target
- $5.18
- Stop
- $3.97
- Upside to target
- +17.5%
- Reward-to-risk
- 1.2:1
The stock trades at 4.5× trailing but 2.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 77 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
IRWD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $665.9M
- P/E (fwd)
- 2.7
- P/E (ttm)
- 4.5
- 52-week range
- $1.88–$5.78
- Off 52-week high
- 23.7%
- RSI (14)
- 77
- Volume vs avg
- 0.91×
- Score today
- 7.6/10